Heart Failure (HF)
Patient Condition
HFrEF (DCM), LVEF 28%, NYHA class III. Enrolled into the clinical trial of iPS cell-derived cardiomyocyte sheet transplantation (iPS-CM sheet) to explore a new way of treating heart failure with regenerative medicine.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Clinical trial screening and preparation | ||
| Cell slice transplantation | ||
| postoperative management | ||
| long-term follow-up |
Treatment Outcome
| before | LVEF 28%, NYHA class III, NT-proBNP 4500 pg/mL, 6-minute walk distance 280m |
|---|---|
| after | LVEF 40%, NYHA class II, NT-proBNP 2200 pg/mL, 6-minute walking distance 390m |
| highlight | The world's first batch of iPS cell myocardial slices were transplanted for the treatment of heart failure, with LVEF increased by 12%, and no serious proarrhythmic events |